Membrane cofactor protein (MCP) of the complement system is a iC3/C3b binding molecule with cofactor activity that has been identified on all human peripheral blood cells except erythrocytes. Human mononuclear and platelet MCP is dimeric with molecular weights of 68,000 and 63,000 and is expressed in three phenotypic patterns. To further determine its tissue distribution, surface-labeled human fibroblast, epithelial, and endothelial cells and cell lines were assessed for the presence of MCP by iC3 affinity chromatography and by immunoprecipitation with a monospecific anti-MCP rabbit polyclonal antibody. All sources of adult and fetal fibroblast and epithelial cells and cell lines examined and umbilical vein endothelial cells expressed MCP. The molecular weight and phenotypic patterns of MCP were similar to those of peripheral blood cells. MCP was synthesized by fibroblast and epithelial cell lines. Solubilized extracts of these cell lines expressed factor I-dependent cofactor activity for the first cleavage of iC3/C3b which was abrogated by removal of MCP. Expression of MCP was modulated by SV40 transformation of two fetal fibroblast lines. There was a 5-to 10-fold increase in expression of MCP and a preferential expression of the lower species such that the phenotypic desigation was changed. The wide tissue distribution and activity profile of MCP suggest that it is likely to play an important role in the regulation of the complement cascade.
Introduction
Membrane cofactor protein (MCP'; formerly named gp45-70) ofcomplement binds iC3/C3b and, less avidly, iC4/C4b (1, 2).
It possesses factor I-dependent cofactor activity (1) (2) (3) for these components and thereby has the potential to inhibit their function in the complement system. MCP is expressed on peripheral blood cells, including granulocytes, T and B lymphocytes, monocytes, and platelets, but not erythrocytes (1, 3, 4) . In all peripheral blood cells except granulocytes, MCP is a dimeric protein with molecular weights of the two species of 68,000 and 63,000 (SDS-PAGE, reducing conditions) (1, 3, (4) (5) (6) . AR individuals express both species but in a trimodal 1. Abbreviations used in this paper: DAF, decay-accelerating factor; MCP, membrane cofactor protein.
distribution in which the quantity of each species expressed is genetically regulated (5) . Two codominantly inherited allelic variants appear to account for the three phenotypic patterns, predominant upper band expression (66% of the population), approximately equal (28%) and lower band predominant (6%) (5) . MCP has been purified (2) and a monospecific polyclonal antibody has been raised (4, 5) . Recently, the derived amino acid sequence of MCP has been determined from a cDNA clone (7) . The most remarkable feature, beginning at its amino terminus, is the presence of four contiguous 60 amino acid repeating units that match the consensus sequence found in a multigene family ofcomplement regulatory proteins (reviewed in references [8] [9] [10] . The remainder ofthe molecule consists of a region rich in serine and threonine (probable site of heavy 0-linked glycosylation), a transmembrane hydrophobic region, and a cytoplasmic tail. The MCP structural gene was localized to human chromosome band 1q32 (7) , which contains other members of the multigene family of complement regulatory and receptor proteins (11, 12) . Utilizing pulse field gel electrophoresis the MCP structural gene has been more precisely mapped. It is located within 100 kb of the 3' end of the CR1 gene and the order of the genes on an -800-kb stretch of DNA at the RCA cluster is MCP-CR1-CR2-DAFC4bp (13) .
Decay accelerating activity and cofactor activity are two important mechanisms that down-regulate the complement cascade at the critical step of C3 activation (reviewed in references 14 and 15). Among complement receptors and regulatory proteins that interact with C3b/C4b, only decay-accelerating factor (DAF) has been shown to have a wide tissue distribution, including most peripheral blood cells (16, 17) , endothelial (18) , glandular, and epithelial cells (19) . DAF (1) .
The following human fibroblast cell lines were obtained from the National Institute of General Medical Sciences Human Genetic Mu-cell line; AG2602, an adult skin fibroblast cell line from the same  donor as AG2603; GM2987, an adult skin fibroblast cell line; IMR90,  a human fetal lung fibroblast cell line (16 wk ofgestation); AG3204, a  precrisis SV40-infected IMR90 cell line, expressing the T antigen on  10% of the cells; AG2804B, a postcrisis SV40-transformed IMR90 cell  line, derived from the AG3204 cell line; AG68 14D, a human fetal lung  fibroblast cell line (12 wk of gestation and formerly designated W138) ; AG7217, a postcrisis SV40-transformed AG6814D cell line; GM0637B, a postcrisis-SV40 transformed daughter of GM0037C which was derived from adult skin. All postcrisis cell lines expressed 100% large T antigen and 1-5% of cells also expressed the V antigen. The postcrisis cell lines expressed the same HLA type and G6PD isoenzyme pattern as the parent cell line (personal communication, Dr. Lorraine Toji, National Institute of General Medical Sciences Human Genetic Mutant Cell Repository).
HEp-2, a cell line established from a carcinoma of the larynx, and HeLa, a cell line derived from a carcinoma ofthe cervix, were obtained from American Type Culture Collection, Rockville, MD. Keratinocytes, derived from normal adult human skin, were isolated and grown in primary culture (generous gift ofAlice Pentland, Division ofDermatology, Washington University School of Medicine) (20) . Endothelial cells were obtained from a primary culture of human umbilical vein and purified and cultured according to previously published methods (generous gift ofPamela Manning and Jitka Olander, Monsanto Laboratories, St. Louis, MO) (21) .
The above cell populations were grown in monolayers in T-flasks in media containing a-MEM with 10% fetal calf serum, 30 mM Hepes buffer, pH 7.3, and fungizone, penicillin, and streptomycin (all provided by the Washington University Tissue Culture Center). The cells were treated with 25 mM trypsin/5 mM EDTA to disrupt the monolayers. Cell suspensions were split 1:3 or 1:4 to increase cell members for experimental conditions (as per supplier's recommendations for cell passage). On day 3 or 4 postpassage (to allow for confluency and normalization of cell membrane proteins), the cells to be used for surface labeling were harvested by scraping or trypsin treatment. The fibroblast cell lines were used before they had undergone 20 passes. For some experiments, HeLa cells were grown in suspension.
Surface labeling. The cells were harvested and washed three times with PBS (150 mM NaCl, 10 mM K2HPO4, 1.5 mM NaH2PO4, pH 7.4). The cells were resuspended in 4 ml PBS and surface-labeled with 125I via a previously described lactoperoxidase method (21, 22) . The cells were solubilized at a concentration of 1 x I07 cells/ml in PBS with 1% NP-40, 2 mM phenylmethylsulfonyl fluoride, 3 mM ethylenediaminetetracetic acid, I gg/ml pepstatin, and 2 mM iodoacetamide.
Biosynthetic labeling. Biosynthetic labeling was performed in 175-ml T-flasks. The monolayers were washed three times with PBS. 4 ml of RPMI with 10% of the normal concentration of glucose and containing 10% dialyzed fetal calf serum were added to each flask.
[3H]Glucosamine (50 yCi per flask) (New England Nuclear, Boston, MA) was added and the flasks were incubated for 18 h at 37°C. At the end ofincubation, the supernatant was aspirated after centrifugation at 800g for 15 min at 4°C. The monolayers were washed three times with PBS and then solubilized in PBS containing 1% NP-40 and the protease inhibitors noted above.
Affinity chromatography. Solubilized cell preparations were centrifuged at 10,000 g for 12 min at 4°C. The supematant was then incubated at room temperature for 60 min with 0.3 ml of either human IgG-(Fraction II; Miles Scientific Div., Naperville, IL) or BSA-(Sigma Chemical Co., St. Louis, MO) Sepharose 4B, (Sigma Chemical Co.) (23) . After centrifugation, the supernatant was diluted to 50 mM NaCl in 1% NP-40 and then rotated for 60 min at room temperature with iC3-Sepharose. After centrifugation, iC3-Sepharose was transferred to a Bio-Rad column (Bio-Rad Laboratories, Richmond, CA) (11 ml) and washed with diluted PBS and 1% NP-40 (50 times the column volume). The column was then eluted with 4 Immunoprecipitation. Immunoprecipitation was performed as previously described (4, 5) . Three preparations of MCP antibody and a matched IgG control were used. A rabbit polyclonal antibody to MCP and two Ig fractions of this antiserum were obtained by precipitation with ammonium sulfate or caprylic acid (Sigma Chemical Co.) (24). The products of immunoprecipitation using MCP antibody were identical with whole antiserum, Ig obtained by ammonium sulfate precipitation, or IgG obtained by caprylic acid precipitation. A mouse anti-human C3b/C4b receptor (CR1) monoclonal antibody (57F) was a generous gift of Eric J. Brown, Washington University School of Medicine (25) . A monoclonal antibody, unknown specificity but ofthe same isotype as the anti-CRI monoclonal, was used as a control. Hybridoma cell line HB-5 secreting IgG2a monoclonal anti-C3d receptor (CR2) was obtained from American Type Culture Collection. Goat anti-human factor H was purchased (Calbiochem-Behring Corp., La Jolla, CA). '25I-factor H was a generous gift of Timothy C. Farries (26) .
The solubilized proteins were eluted from Staphylococcus aureus protein A (Cowan I strain; Calbiochem-Behring Corp.) with disintegration buffer (see above).
Cofactor assay. Cells were scraped from the flasks, washed three times in PBS, and then solubilized in PBS, 1% NP-40, and the four protease inhibitors. Factor I was purified as described (26, 27) . CR1 was used as a positive control and it was purified as described (25) .
For the fluid-phase cofactor assays, '25I-iC3 was prepared using the chloramine T method (28) . '25I-iC3 was incubated with solubilized preparations of cells with or without factor I for I h at 37°C. The samples were then heated for 5 min at 80°C in disintegration buffer (see above) containing 5% ,j-mercaptoethanol. A cofactor assay employing '25I-C3b-Sepharose also was employed (25) .
SDS-PAGE and autoradiography. SDS-PAGE was performed as previously described using either 7.5%, 9%, or 6-18% polyacrylamide (1, 2). All samples were loaded onto a 3% stacking gel. Samples were reduced by treatment with 5% s-mercaptoethanol and heating at 80°C for 5 min. Quantification of the relative intensity of bands on autoradiographs was performed with a laser densitometer (Ultroscan XL; LKB Prodkter, Bromma, Sweden) (5).
General experimental design. Cells or cell lines were surface-labeled with 125I or biosynthetically labeled with [3H]glucosamine, solubilized, and then subjected to iC3-affinity chromatography or immunoprecipitation. Control columns consisting of BSA-Sepharose or IgG-Sepharose were employed in all experiments using iC3-affinity columns. A nonspecific polyclonal rabbit antiserum or a monoclonal mouse antibody of unknown specificity was employed as a control in all immunoprecipitation experiments. In some cases, the eluates from the iC3-affinity column were dialyzed and then immunoprecipitated. The eluates and precipitates were analyzed by SDS-PAGE (under reducing and nonreducing conditions) followed by autoradiography.
Results
Fibroblast cell lines. An adult human lung fibroblast cell line (AG2603) was analyzed for its expression of MCP. After surface labeling, MCP was identified in the solubilized cell extracts both by iC3-affinity chromatography and by immunoprecipitation ( Fig. 1 A) . No other iC3 binding protein was identified. On AG2603 MCP is expressed as a predominantly upper-band pattern in a ratio of the upper to the lower species of 90/10 (5). This is the most common phenotypic variant, observed in 65% of individuals. Skin fibroblasts (AG2602) from the same donor as the lung fibroblasts exhibited the same molecular weight and also a predominantly upper-band pattern ( Fig. 1 B) . (Fig. 1 B) . A comparison of MCP isolated from PBMC, a fibroblast cell line and an epithelial cell line are shown in Fig. 1 (Fig. 2 A) (Fig. 2 B) . Densitometric scanning ofthe MCP isolated from surface-and biosynthetically labeled preparations demonstrated identical molecular weights and upper to lower band ratio of 30/70. MCP was also synthesized by AG2603, a fibroblast line (not shown). The incubation media of both HEp-2 and AG2603 were assessed for MCP by immunoprecipitation and affinity chromatography, but no protein of a molecular weight similar to that of MCP was isolated (not shown).
Endothelial cells. Low-passage umbilical vein endothelial cells were analyzed for MCP. A prominent broad species with the expected molecular weight of MCP was identified by affinity chromatography and by immunoprecipitation (Fig. 3) . Upon longer exposure a distinct two-band pattern was ob- served and by densitometric scanning > 80% of the counts were in the upper species. No protein comparable in molecular weight to CR1 or CR2 was isolated by iC3 affinity chromatography (Fig. 3) or by immunoprecipitation with monoclonal antibodies to CR1 or CR2 (not shown). As has been observed in the other cell types (1, 3, 4, 5) , upon reduction the molecular weight of the two species of MCP was greater.
Cofactor activity ofepithelial andfibroblast cell lines. Solubilized preparations of HEp-2 or AG2603, harvested from monolayers either by scraping or trypsin treatment, possessed factor I-dependent cofactor activity for iC3 (Fig. 4 A) . The decrease in the quantity of a-chain paralleled the appearance of its 65,000-and 43,000-mol wt proteolytic fragments (29) . The molecular weights of the a'1 and a'2 fragments generated with purified CR1 or solubilized preparations of HEp-2 were identical. If the solubilized HEp-2 or AG2603 preparations were first precleared of MCP by immunoprecipitation, cofactor activity was abolished (Fig. 4, B and C) . This result combined with the fact that no CR1, factor H, or CR2 was isolated from these solubilized preparations by affinity chromatogtaphy ( Figs. 1 and 2) or immunoprecipitation (not shown), indicates that MCP is responsible for this cofactor activity. Solubilized preparations from IMR90 and AG6814D, fibroblasts derived from normal fetal lung, also possessed factor I-dependent cofactor activity (not shown). In other experiments, C3b-Sepharose, rather than iC3, was employed. Table I ). IMR90, a fibroblast cell 1 2 3 4 5 6 7 Figure 3 . MCP of human umbilical vein endothelial cells. Cells were surface labeled. The samples in lanes 3 and 4 were first subjected to affinity chromatography and then the eluates from the column were immunoprecipitated. Abbreviations as per Fig. 1 . Autoradiograph, SDS-PAGE (7.5%).
line derived from normal 16-wk gestation fetal lung, expresses slightly more of the upper species (60/40) of MCP. AG2804B expresses more of the lower species (20/80). Furthermore, based on densitometnc scanning, at least fivefold more MCP was expressed by AG2804B than the parent IMR90 (equivalent cell numbers were analyzed in lanes I and 4). These patterns were observed in multiple experiments.
To further evaluate effects of transformation on expression, similar experiments were performed with two additional cell sources. In one instance, the parental cell line was a 12-wk-old human fetal lung fibroblast (AG6814D) and the daughter was a postcrisis SV40-transformed cell line (AG7217). The parent expressed MCP as an upper species predominant pattern (90/10) and the daughter as an approximately equal (55/45) pattern (Fig. 5 B) . Again, an approximately fivefold increase in expression ofMCP was noted in the SV40-transformed cell line and there was preferential expression of the lower species. This increase was consistently observed in several experiments in which affinity chromatography or immunoprecipitation was utilized to isolate MCP. In addition, a cofactor assay utilizing solubilized preparations of AG6814D and AG7217 demonstrated an approximately fivefold increase in cofactor activity ( In another case, the parental cell line was a normal adult human skin (GM0037A) and the daughter was a postcrisis SV40-transformed cell line (GM0637B). SV40 transformation did not result in a change in the expression of MCP (Fig. 5 C) . Also, the pattern of MCP expression of the precrisis cell line (GM3204) was similar to the parent.
Discussion
Previous studies demonstrated that MCP is expressed by all human peripheral blood cell populations except erythrocytes (1, 3, 4, 5) . In this report MCP was demonstrated to be present on fibroblast, epithelial, and endothelial cells. First, MCP was identified antigenically by its precipitation with a monospecific rabbit polyclonal antibody to MCP. Secondly, the same protein that was isolated by immunoprecipitation specifically bound to iC3 affinity columns. Thirdly, solubilized preparaa, to immunoprecipitation with a polyclonal antibody to MCP, the cofactor activity was abrogated, demonstrating that MCP is the protein with cofactor activity in these preparations. (16) . The cellular distribution of MCP also includes most peripheral blood cells, endothelial, and epithelial cells and fibroblasts (4, this report). DAF prevents the assembly and promotes the decay of the C3 convertases formed on the same cell surfaces on which DAF is located (intrinsic activity) (reviewed in references 14 and 33). DAF does not, however, irreversibly inactivate the C4b or C3b and, after interaction with DAF, C3b or C4b molecules still possess hemolytic potential. In contrast, purified or solubilized cell extracts containing MCP serve as a cofactor for inactivation by factor I, irreversibly altering C3b or C4b. The resulting proteolytic cleavage product, C3bi or C4bi, no longer may serve as a nidus for the convertase. Thus purified MCP has a related but complementary activity profile and a similar wide tissue distribution to DAF.
Predominant expression of the lower species of MCP was observed in four of the five immortalized or transformed cell lines including cells derived from two human malignancies (HEp-2 and HeLa) characterized in this study. This lower species predominant phenotypic pattern is observed in only 6% of the normal population (5) . The phenotypic pattern is stable over time in a given individual and is the same on all cell types expressing MCP (5, 6) . Although these HEp-2 and HeLa could have both been derived from individuals expressing this uncommon phenotype, it is also possible that the expression of MCP was modulated by the malignant or immortalized state.
Because the parent cells were available, several fibroblast cell lines that had been immortalized by SV40 were chosen to evaluate this question (see Table I ). SV40 transformation of two fetal cell lines resulted in a quantitatively greater (at least fivefold) amount of MCP being expressed and relatively much more of the lower species than the parent cell, thereby altering the MCP phenotype. Regulation of host protein synthesis by SV40 virus during infection and transformation has been demonstrated in several other in vitro model systems (34) (35) (36) (37) (38) (39) (40) and further molecular and functional analysis of this alteration in MCP expression should be informative.
In summary, a membrane glycoprotein ofthe complement system has been demonstrated herein to have a broad tissue distribution and to have its expression modified in fibroblasts by SV40 transformation. The purified protein has previously been shown to possess cofactor activity and to bind C3b. MCP in detergent solubilized cell extracts has the same functional profile. Our working hypothesis is that MCP, along with DAF, functions in an intrinsic fashion to protect autologous cells from complement mediated damage. It should now be possible, by the use of antibodies to MCP and transfection systems, to more definitely characterize its function on intact cells.
